Motif Bio Plc announced the appointment of Pete A. Meyers as Chief Financial Officer and Rajesh B. Shukla, Ph.D. as Vice President, Clinical Operations. Mr. Meyers joins the Company from TetraLogic Pharmaceuticals Corporation where he was CFO and Treasurer. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Bob Bertoldi, Motif Bio's current CFO and Director, will transition his CFO responsibilities to Mr. Meyers but will continue as a Director.

Dr. Shukla is an accomplished clinical operations professional with extensive experience in Research, Development and Medical Affairs. He joins the Company from ACORDA Therapeutics where he was Senior Medical Director Clinical Development and Medical Affairs. The Company has also appointed Jonathan Gold, currently a non-executive director of Motif Bio plc, as a strategic financial consultant under a consulting agreement (the "Consulting Agreement") to assist the Company in its capital raising plans.